The effectiveness of vitamin D as an alternative to FDA ‐approved treatment and other therapies for managing vulvovaginal atrophy and sexual inactivity in postmenopausal women. A systematic review and meta‐analysis
International Journal of Gynecology & Obstetrics · 2025
DOI: 10.1002/ijgo.70011 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Gynecology & Obstetrics, 2025. Verfasst von Eman Youssef und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. Hauptthemen laut MEDLINE: Postmenopause, Vitamin D, Vagina, Vulva. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Background
Vulvovaginal atrophy (VVA) and sexual inactivity (SI) are prevalent among postmenopausal women (PMW). While hormonal therapies show significant improvement, non‐hormonal therapies are considered the first‐line for breast cancer women. However, vaginal hormonal therapies are unavailable in all countries, particularly developing countries such as the middle east, and there are no studies that have tested these therapies in women either with a history of breast cancer or those taking endocrine therapies for their cancer.
Objective
We conducted this meta‐analysis to evaluate the effectiveness of vitamin D (VD), whether alone or in combination with other therapies, in managing VVA and SI in PMW. Search Strategy A systematic literature search was undertaken on four electronic databases (Web of Science, PubMed, Cochrane, and Scopus) from inception until June 2023. Selection Criteria The randomized controlled trials (RCTs) that used the vaginal maturation index (VMI) and vaginal pH to measure VVA and vaginal dryness and the female sexual function index (FSFI) to measure SI were included in the meta‐analysis. Main Results Eight RCTs (608 PMW) were included, and 222 were assigned to the VD arm. For the oral VD subgroup, there was no statistically significant improvement in the mean difference (MD) of VMI (MD –7.62, 95% confidence interval [CI]: −23.84, 8.59). However, VMI's topical VD subgroup was statistically significant (25.16; 95% CI: 18.74, 31.59). For topical form, the total FSFI score (0.24; 95% CI: −1.72, 2.20) and all FSFI domains did not demonstrate statistically significant improvement except arousal (0.56; 95% CI: 0.12, 1.00). Vaginal pH's oral VD subgroup showed statistically significant improvement (−0.27, 95% CI: −0.50, −0.05) compared to the topical VD. Topical VD subgroup (24.45; 95% CI: 7.14, 41.77) showed a statistically significant increase of vaginal superficial cells, in contrast to the oral VD subgroup (3.25; 95% CI: −5.44, 11.96).
Conclusion
Topical VD showed significant improvements in VMI and the arousal subscale of FSFI, whereas oral VD had no substantial improvement except in vaginal pH. VD alone is not a sufficient alternative to other available treatments, and further RCTs are needed to evaluate its effectiveness without any combination with other drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Faculty of Medicine, Zagazig University, Zagazig, Egypt.
- Clinical Pharmacy Department, Faculty of Deraya University, Minia, Egypt.
- Consultant Gynecology, New Cairo Hospital, Cairo, Egypt.
ORCID-Profile: Eman Youssef, Mostafa Saad Badie, Doaa Ismail, Aliaa Gamal, Hala Mohamed Eldamanhoury
Zitieren
APA
Youssef, E., Badie, M. S., Ismail, D., Gamal, A., & Eldamanhoury, H. M. (2025). The effectiveness of vitamin D as an alternative to FDA ‐approved treatment and other therapies for managing vulvovaginal atrophy and sexual inactivity in postmenopausal women. A systematic review and meta‐analysis. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.70011
Vancouver
Youssef E, Badie MS, Ismail D, Gamal A, Eldamanhoury HM. The effectiveness of vitamin D as an alternative to FDA ‐approved treatment and other therapies for managing vulvovaginal atrophy and sexual inactivity in postmenopausal women. A systematic review and meta‐analysis. International Journal of Gynecology & Obstetrics. 2025. doi:10.1002/ijgo.70011
BibTeX
@article{Youssef2025,
author = {Youssef, Eman and Badie, Mostafa Saad and Ismail, Doaa and Gamal, Aliaa and Eldamanhoury, Hala Mohamed},
title = {The effectiveness of vitamin D as an alternative to FDA ‐approved treatment and other therapies for managing vulvovaginal atrophy and sexual inactivity in postmenopausal women. A systematic review and meta‐analysis},
journal = {International Journal of Gynecology & Obstetrics},
year = {2025},
doi = {10.1002/ijgo.70011}
}
EUVIMED